MedTrace Logo

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

NCT06844357 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-04-06

No results posted yet for this study

Summary

This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC. The results will provide valuable insights into the potential benefits of TATE as a novel treatment option for HCC.

Conditions

Interventions

DRUG

tirapazamine

Intra-arterial injection into the tumor feeding artery

PROCEDURE

Transarterial Embolization (TAE)

Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia

PROCEDURE

TACE

TACE with epirubicin

Sponsors & Collaborators

  • Zhejiang Raygene Pharmaceuticals Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Gaojun Teng, M.D · Zhongda Hospital

  • Jiansong Ji, M.D · The Central Hospital of Lishui City

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-27
Primary Completion
2029-04-01
Completion
2029-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06844357 on ClinicalTrials.gov